A Bibliometric Analysis of the WoSCC Literature on the Use of Selective Serotonin Reuptake Inhibitors as Antidepressants

Drug Des Devel Ther. 2024 Nov 4:18:4961-4974. doi: 10.2147/DDDT.S476680. eCollection 2024.

Abstract

Background: Many studies have been conducted on the use of selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression. However, the overall trends in research publications in this field remain elusive. There is still little quantitative analysis of the literature in this field. Therefore, we conducted a bibliometric analysis to explore the research patterns surrounding SSRIs for depression, aiming to gain a deeper understanding of their development and impact.

Methods: Publications about the use of SSRIs for the treatment of depression were identified in the Web of Science Core Collection. Visualization analysis was performed with Bibliometrix, VOSviewer, and CiteSpace.

Results: A total of 1149 publications published from 1990 to 2024 were included in the bibliometric analysis. Since 1990, the annual number of published papers has increased annually, reaching the maximum value of output in 2004. Fitted curve showed that after 2004, the number of publications per year was essentially stable The United States dominates the field. Among these institutions, University of Pittsburgh excels in this field. Fava M has the highest scientific productivity and extensive academic influence. European Neuropsychopharmacology is the most active journal in this field. The three most relevant keywords were "fluoxetine", "double-blind", and "major depression". The trend topics in recent years were "connectivity", "c-reactive protein", and "anhedonia".

Conclusion: Research on the use of SSRIs for the treatment of depression continues to receive increased attention but still requiraes further exploration and innovation. We further analyze the current research hotspots and frontiers in this field.

Keywords: bibliometrics; depression; double-blind; fluoxetine; major depression; selective serotonin reuptake inhibitors.

MeSH terms

  • Antidepressive Agents* / therapeutic use
  • Bibliometrics*
  • Depression / drug therapy
  • Humans
  • Selective Serotonin Reuptake Inhibitors* / therapeutic use

Substances

  • Selective Serotonin Reuptake Inhibitors
  • Antidepressive Agents

Grants and funding

This work was supported by the Southwest Medical University Student Innovation and Entrepreneurship Project Fund (Grant Numbers: 202310632045 and 202310632059).